Literature DB >> 12382079

Electrophysiological and antiarrhythmic effects of the novel I(Kur) channel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the I(Kr) blockers dofetilide, azimilide, d,l-sotalol and ibutilide.

Karsten Knobloch1, Joachim Brendel, Stefan Peukert, Björn Rosenstein, Andreas E Busch, Klaus J Wirth.   

Abstract

Inhibition of the cardiac Kv1.5 channel, the molecular base for the human cardiac ultrarapid delayed rectifier potassium current (I(Kur)), is considered a new promising atrial selective antiarrhythmic concept since this channel is presumed to contribute to atrial but not ventricular repolarization in the human heart. In a previous study in pigs we found clear baseline differences in refractoriness between left and right atrium with shorter effective refractory periods (ERPs) of the left atrium associated with a high left atrial vulnerability for tachyarrhythmias. In this newly established model we compared atrial and ventricular effects of two novel I(Kur) blockers, S9947 and S20951, with the I(Kr) blockers dofetilide, azimilide, ibutilide and d,l-sotalol. In pentobarbital anesthetized pigs (n=45) we determined ERPs in the free walls of both atria with the S1-S2-stimulus method at three basic cycle lengths (BCL 240/300/400 ms) and QTc-intervals. The incidence of atrial tachyarrhythmias triggered by the S2-extrastimulus of the left atrium was evaluated (referred to as left atrial vulnerability). In contrast to I(Kr) blockade, I(Kur) blockade had no effect on the QT-interval, but prolonged the atrial ERP. The I(Kur) blockers were significantly stronger on left atrial ERP, I(Kr) blockers on right atrial ERP (P<0.05 for all compounds tested). At 240 ms BCL the I(Kur) blocker S20951, 3 mg/kg, prolonged left vs. right atrial ERP by 28+/-5 ms vs. 12+/-3 ms and S9947, 3 mg/kg, by 45+/-7 ms vs. 19+/-6 ms. By contrast the effect of dofetilide, 10 microg/kg, was stronger on the right than left atrium (47+/-6 ms vs. 25+/-2 ms), a profile also found with azimilide (5 mg/kg, 43+/-3 ms vs. 17+/-3 ms), ibutilide (15 microg/kg, 70+/-10 ms vs. 29+/-4 ms) and d,l-sotalol (1.5 mg/kg, 57+/-6 ms vs. 36+/-4 ms). The I(Kur) blockers, S20951and S9947, significantly decreased left atrial vulnerability (-82% and -100%, respectively, P<0.01) in contrast to the selective I(Kr) blocker dofetilide (-14%; n.s.). In conclusion, I(Kur) and I(Kr) blockers showed substantial differences in their atrial and ventricular actions in pigs. I(Kr) blockers were stronger on right atrial ERP, I(Kur) blockers on left atrial ERP, suggesting interatrial differences in the expression of potassium channels. In contrast to selective I(Kr) blockade, I(Kur) blockade inhibited left atrial vulnerability and had no effect on the QT-interval. Thus, blockade of I(Kur) seems to be a promising atrial selective antiarrhythmic concept.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12382079     DOI: 10.1007/s00210-002-0599-x

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  13 in total

1.  Modeling the effect of Kv1.5 block on the canine action potential.

Authors:  Joachim Almquist; Mikael Wallman; Ingemar Jacobson; Mats Jirstrand
Journal:  Biophys J       Date:  2010-11-03       Impact factor: 4.033

2.  Rate-Dependent Role of IKur in Human Atrial Repolarization and Atrial Fibrillation Maintenance.

Authors:  Martin Aguilar; Jianlin Feng; Edward Vigmond; Philippe Comtois; Stanley Nattel
Journal:  Biophys J       Date:  2017-05-09       Impact factor: 4.033

3.  Symmetric kv1.5 blockers discovered by focused screening.

Authors:  Jonas Boström
Journal:  ACS Med Chem Lett       Date:  2012-08-16       Impact factor: 4.345

4.  Pergolide block of the cloned Kv1.5 potassium channels.

Authors:  Imju Jeong; Bok Hee Choi; Sang June Hahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-07-05       Impact factor: 3.000

5.  Specific pattern of ionic channel gene expression associated with pacemaker activity in the mouse heart.

Authors:  Céline Marionneau; Brigitte Couette; Jie Liu; Huiyu Li; Matteo E Mangoni; Joël Nargeot; Ming Lei; Denis Escande; Sophie Demolombe
Journal:  J Physiol       Date:  2004-10-21       Impact factor: 5.182

6.  Global gene expression in human myocardium-oligonucleotide microarray analysis of regional diversity and transcriptional regulation in heart failure.

Authors:  Stefan Kääb; Andreas S Barth; Daniel Margerie; Martin Dugas; Mathias Gebauer; Ludwig Zwermann; Sylvia Merk; Arne Pfeufer; Klaus Steinmeyer; Markus Bleich; Eckart Kreuzer; Gerhard Steinbeck; Michael Näbauer
Journal:  J Mol Med (Berl)       Date:  2004-04-23       Impact factor: 4.599

Review 7.  Voltage-gated potassium channels as therapeutic targets.

Authors:  Heike Wulff; Neil A Castle; Luis A Pardo
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

8.  Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels.

Authors:  Heinz Gögelein; J Brendel; K Steinmeyer; C Strübing; N Picard; D Rampe; K Kopp; A E Busch; M Bleich
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-08-31       Impact factor: 3.000

9.  Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter.

Authors:  Javier E Banchs; Deborah L Wolbrette; Soraya M Samii; Erica D Penny-Peterson; Parag P Patel; Sallie K Young; Mario D Gonzalez; Gerald V Naccarelli
Journal:  J Interv Card Electrophysiol       Date:  2008-08-08       Impact factor: 1.900

10.  Inhibitory actions of the phosphatidylinositol 3-kinase inhibitor LY294002 on the human Kv1.5 channel.

Authors:  J Wu; W-G Ding; H Matsuura; K Tsuji; W-J Zang; M Horie
Journal:  Br J Pharmacol       Date:  2009-01-16       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.